Development of a Subcutaneous Formulation for Trastuzumab - Nonclinical and Clinical Bridging Approach to the Approved Intravenous Dosing Regimen-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Development of a Subcutaneous Formulation for Trastuzumab - Nonclinical and Clinical Bridging Approach to the Approved Intravenous Dosing Regimen

Published:2012-08-23 Issue:09 Volume:62 Page:401-409
ISSN:0004-4172
Container-title:Arzneimittelforschung
language:en
Short-container-title:Arzneimittelforschung

Author:

Bittner B.¹²,Richter W.³,Hourcade-Potelleret F.⁴,McIntyre C.¹,Herting F.⁵,Zepeda M.⁶,Schmidt J.²

Affiliation:

1. F. Hoffmann-La Roche Ltd., Clinical Pharmacology, Basel, Switzerland

2. F. Hoffmann-La Roche Ltd., Pharma Medicines Global Product Strategy, Basel, Switzerland

3. F. Hoffmann-La Roche Ltd., Nonclinical Safety, Basel, Switzerland

4. F. Hoffmann-La Roche Ltd., Clinical Modeling & Simulation, Basel, Switzerland

5. Roche Diagnostics GmbH, Penzberg, Germany

6. Halozyme Therapeutics Inc., San Diego, CA, USA

Publisher

Georg Thieme Verlag KG

Subject

Drug Discovery

Link

http://www.thieme-connect.de/products/ejournals/pdf/10.1055/s-0032-1321831.pdf

Cited by 45 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Predicting Human Subcutaneous Bioavailability of Therapeutic Monoclonal Antibodies from Systemic Clearance and Volume of Distribution;Molecular Pharmaceutics;2024-09-03

2. Monoclonal Antibodies: From Structure to Therapeutic Application;Pharmaceutical Biotechnology;2024

3. Advancing Subcutaneous Dosing Regimens for Biotherapeutics: Clinical Strategies for Expedited Market Access;BioDrugs;2023-10-13

4. Effect of siltuximab, omalizumab, infliximab, pembrolizumab and vedolizumab on selected haematological and biochemical parameters in a pig model;Polish Journal of Veterinary Sciences;2023-07-26

5. Infective complications in cancer patients treated with subcutaneous versus intravenous trastuzumab and rituximab: An individual patient data meta-analysis;Journal of Oncology Pharmacy Practice;2023-06-16

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3